Cas:41057-04-9 2-nitro-3-thiophenecarbaldehyde manufacturer & supplier

Chemical Name:2-nitro-3-thiophenecarbaldehyde

CAS.NO:41057-04-9

Synonyms:2-Nitro-thiophene-3-carbaldehyde;2-nitro-3-thiophenecarbaldhyde;2-nitro-thiophene-3-carbaldehyde;2-nitrothiophene-3-carbaldehyde;2-Nitro-thiophen-3-carbaldehyd;3-formyl-2-nitrothiophene;nitro-3-thiophenecarbaldehyde

Molecular Formula:C₅H₃NO₃S

Molecular Weight:157.14700

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:91.13000

Exact Mass:156.98300

LogP:1.99200

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Nitro-thiophene-3-carbaldehyde chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,nitro-3-thiophenecarbaldehyde physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-nitrothiophene-3-carbaldehyde Use and application,2-Nitro-thiophene-3-carbaldehyde technical grade,usp/ep/jp grade.

Related News: As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2-nitro-3-thiophenecarbaldehyde manufacturer Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit the scene last year with Sarclisa. Now, just as the competition’s slated to intensify, the U.S. company is building its case with new patient survival data. 2-nitro-3-thiophenecarbaldehyde supplier As a result, the Company��s platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. 2-nitro-3-thiophenecarbaldehyde vendor Due to the time-consuming process of EIA approval and EIA acceptance for newly-built projects, and environmental protection supervision policies are becoming increasingly tight, the company strives to improve capacity utilization through reasonable equipment layout when designing and constructing capacity. 2-nitro-3-thiophenecarbaldehyde factory Bulk bulk medicines: overcapacity, low prices, future capacity and output will be reduced, and it is possible to transfer foreign production.